• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.

作者信息

Pekna M, Borowiec J, Fagerhol M K, Venge P, Thelin S

机构信息

Department of Clinical Immunology and Transfusion Medicine, University Hospital, Uppsala, Sweden.

出版信息

Scand J Thorac Cardiovasc Surg. 1994;28(1):5-11. doi: 10.3109/14017439409098703.

DOI:10.3109/14017439409098703
PMID:7939508
Abstract

The combined effect of heparin coating of cardiopulmonary bypass (CPB) circuits and reduced dose of systemic heparin on activation of the complement system and blood leukocytes was investigated in 19 patients undergoing coronary bypass surgery and randomly allocated to two groups. A heparin-coated CPB circuit together with a 50% reduction of the standard heparin dose were used for ten patients (HC group), and a standard CPB circuit with a standard heparin dose (300 IU/kg) for nine (C group). Significant rise in the levels of neutrophil-derived myeloperoxidase, lactoferrin and calprotectin were observed during CPB in both groups, but the total accumulated levels were significantly lower in the HC than in the C group (p < 0.05). Complement activation, assessed from levels of C3a and terminal complement complexes was similar in both groups. The lower levels of myeloperoxidase, lactoferrin and calprotectin during CPB in the HC group indicate that surface modification with end-point attached heparin enhances the biocompatibility of CPB.

摘要

相似文献

1
Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass.
Scand J Thorac Cardiovasc Surg. 1994;28(1):5-11. doi: 10.3109/14017439409098703.
2
Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment.使用肝素涂层设备进行体外循环期间血小板、粒细胞和补体激活的变化。
Artif Organs. 1996 Jul;20(7):767-76. doi: 10.1111/j.1525-1594.1996.tb04538.x.
3
Complement activation during cardiopulmonary bypass: effects of immobilized heparin.体外循环期间的补体激活:固定化肝素的作用。
Ann Thorac Surg. 1994 Aug;58(2):421-4. doi: 10.1016/0003-4975(94)92219-5.
4
Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery.冠状动脉搭桥手术中肝素涂层体外循环回路
Artif Organs. 1996 Aug;20(8):936-40. doi: 10.1111/j.1525-1594.1996.tb04573.x.
5
High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes.肝素涂层体外循环中的高剂量与低剂量肝素:补体和粒细胞的激活
Ann Thorac Surg. 1995 Dec;60(6):1755-61. doi: 10.1016/0003-4975(95)00763-6.
6
Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation.完全肝素涂层体外循环和低肝素剂量可减少补体和粒细胞激活。
Eur J Cardiothorac Surg. 1996;10(1):54-60. doi: 10.1016/s1010-7940(96)80266-1.
7
Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery.体外循环回路肝素涂层对冠状动脉搭桥手术期间体外氧自由基产生的影响。
Artif Organs. 1996 Sep;20(9):1008-16. doi: 10.1111/j.1525-1594.1996.tb04588.x.
8
Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.肝素涂层回路可减少体外循环期间肿瘤坏死因子α的形成。
Acta Anaesthesiol Scand. 1996 Mar;40(3):311-7. doi: 10.1111/j.1399-6576.1996.tb04438.x.
9
Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.体外循环中开路与闭路生物相容性的比较研究。
Artif Organs. 1999 Jun;23(6):547-51. doi: 10.1046/j.1525-1594.1999.06401.x.
10
Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.体外循环回路的Duraflo II涂层可减少补体激活,但不影响粒细胞酶的释放:一项欧洲多中心研究。
Eur J Cardiothorac Surg. 1997 Feb;11(2):320-7. doi: 10.1016/s1010-7940(96)01062-7.

引用本文的文献

1
Functional and clinical aspects of the myelomonocyte protein calprotectin.髓单核细胞蛋白钙卫蛋白的功能及临床方面
Mol Pathol. 1997 Jun;50(3):113-23. doi: 10.1136/mp.50.3.113.